share_log

Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170

Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170

Evercore ISI集團維持對sarepta therapeutics的買入評級,將目標股價下調至170美元
Benzinga ·  2024/11/07 22:08  · 評級/大行評級

Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and lowers the price target from $179 to $170.

Evercore ISI集團分析師Gavin Clark-Gartner維持對sarepta therapeutics(納斯達克:SRPT)的跑贏市場評級,並將價格目標從179美元降至170美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論